Multivariate analysis--impact of SPM on OS
| Covariate . | N . | Hazard ratio . | 95% Hazard ratio confidence limits . | P-value . | |
|---|---|---|---|---|---|
| Time-dependent: SPM | |||||
| No | - | 1 | Reference | <.0001 | |
| Yes | - | 3.85 | 2.95 | 5.02 | <.0001 |
| Baseline covariates | |||||
| Gender | |||||
| Female | 1791 | 1.00 | Reference | .2683 | |
| Male | 2155 | 1.09 | 0.94 | 1.27 | .2683 |
| Race | |||||
| Black | 1356 | 1.00 | Reference | .0129 | |
| White | 2300 | 1.27 | 1.07 | 1.51 | .0068 |
| Other | 204 | 0.82 | 0.53 | 1.25 | .3492 |
| Missing | 86 | 0.98 | 0.54 | 1.75 | .9351 |
| Karnofsky score | |||||
| ≥90 | 2076 | 1.00 | Reference | .009 | |
| <90 | 1796 | 1.27 | 1.09 | 1.49 | .0021 |
| Missing | 74 | 1.16 | 0.63 | 2.12 | .6297 |
| HCT-CI | |||||
| 0 | 1030 | 1.00 | Reference | .1121 | |
| 1-2 | 1237 | 1.03 | 0.84 | 1.27 | .7629 |
| 3+ | 1659 | 1.21 | 1.00 | 1.47 | .0547 |
| Missing | 20 | 0.38 | 0.05 | 2.69 | .329 |
| ISS stage at diagnosis | |||||
| Stage I | 1231 | 1.00 | Reference | <.0001 | |
| Stage II | 1104 | 1.31 | 1.05 | 1.62 | .0152 |
| Stage III | 712 | 1.91 | 1.54 | 2.38 | <.0001 |
| Missing | 899 | 1.39 | 1.11 | 1.74 | .0046 |
| Cytogenetics | |||||
| Standard/Normal Risk | 2496 | 1.00 | Reference | <.0001 | |
| High risk | 1114 | 2.11 | 1.79 | 2.48 | <.0001 |
| Missing | 336 | 1.48 | 1.13 | 1.95 | .0048 |
| Lines of chemotherapy | |||||
| 1 | 2856 | 1.00 | Reference | .0005 | |
| 2+ | 929 | 1.40 | 1.18 | 1.65 | <.0001 |
| Missing | 161 | 1.04 | 0.66 | 1.64 | .8805 |
| Disease status before transplant | |||||
| sCR/CR | 611 | 1.00 | Reference | .0081 | |
| VGPR | 1538 | 1.14 | 0.89 | 1.46 | .3154 |
| PR | 1520 | 1.22 | 0.95 | 1.56 | .1126 |
| SD/PD/Relapse | 255 | 1.74 | 1.25 | 2.41 | .0009 |
| Missing | 22 | 2.24 | 0.82 | 6.13 | .1175 |
| Covariate . | N . | Hazard ratio . | 95% Hazard ratio confidence limits . | P-value . | |
|---|---|---|---|---|---|
| Time-dependent: SPM | |||||
| No | - | 1 | Reference | <.0001 | |
| Yes | - | 3.85 | 2.95 | 5.02 | <.0001 |
| Baseline covariates | |||||
| Gender | |||||
| Female | 1791 | 1.00 | Reference | .2683 | |
| Male | 2155 | 1.09 | 0.94 | 1.27 | .2683 |
| Race | |||||
| Black | 1356 | 1.00 | Reference | .0129 | |
| White | 2300 | 1.27 | 1.07 | 1.51 | .0068 |
| Other | 204 | 0.82 | 0.53 | 1.25 | .3492 |
| Missing | 86 | 0.98 | 0.54 | 1.75 | .9351 |
| Karnofsky score | |||||
| ≥90 | 2076 | 1.00 | Reference | .009 | |
| <90 | 1796 | 1.27 | 1.09 | 1.49 | .0021 |
| Missing | 74 | 1.16 | 0.63 | 2.12 | .6297 |
| HCT-CI | |||||
| 0 | 1030 | 1.00 | Reference | .1121 | |
| 1-2 | 1237 | 1.03 | 0.84 | 1.27 | .7629 |
| 3+ | 1659 | 1.21 | 1.00 | 1.47 | .0547 |
| Missing | 20 | 0.38 | 0.05 | 2.69 | .329 |
| ISS stage at diagnosis | |||||
| Stage I | 1231 | 1.00 | Reference | <.0001 | |
| Stage II | 1104 | 1.31 | 1.05 | 1.62 | .0152 |
| Stage III | 712 | 1.91 | 1.54 | 2.38 | <.0001 |
| Missing | 899 | 1.39 | 1.11 | 1.74 | .0046 |
| Cytogenetics | |||||
| Standard/Normal Risk | 2496 | 1.00 | Reference | <.0001 | |
| High risk | 1114 | 2.11 | 1.79 | 2.48 | <.0001 |
| Missing | 336 | 1.48 | 1.13 | 1.95 | .0048 |
| Lines of chemotherapy | |||||
| 1 | 2856 | 1.00 | Reference | .0005 | |
| 2+ | 929 | 1.40 | 1.18 | 1.65 | <.0001 |
| Missing | 161 | 1.04 | 0.66 | 1.64 | .8805 |
| Disease status before transplant | |||||
| sCR/CR | 611 | 1.00 | Reference | .0081 | |
| VGPR | 1538 | 1.14 | 0.89 | 1.46 | .3154 |
| PR | 1520 | 1.22 | 0.95 | 1.56 | .1126 |
| SD/PD/Relapse | 255 | 1.74 | 1.25 | 2.41 | .0009 |
| Missing | 22 | 2.24 | 0.82 | 6.13 | .1175 |